New hope for heart attack patients: can a common blood thinner prevent strokes?

NCT ID NCT05892042

Recruiting now Disease control Sponsor: Jilin University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding the blood thinner rivaroxaban (Xarelto) to standard care helps dissolve dangerous blood clots in the heart after a major heart attack. Researchers will track 320 participants to see if the drug reduces strokes and other complications. The goal is to find a better way to manage these clots and improve recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rivaroxaban (Xarelto)
What this could lead to: If successful, this could provide a clearer, safer treatment plan for dissolving dangerous heart clots after a heart attack, reducing stroke risk.
What could go wrong: This is a relatively small, early-stage study without a placebo control, so results may not be definitive. Bleeding risk from blood thinners is a known concern.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEFT VENTRICULAR THROMBUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEFT VENTRICULAR THROMBUS ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)

Contacts and locations

Locations

Jilin university
RECRUITING

Changchun, Jilin, 130000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.